ImmunoCellular Therapeutics is a clinical-stage company that is developing immune-based therapies to diagnose and treat brain and other cancers. The company has begun a Phase II trial of its lead product candidate, ICT-107, which is a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma.
The company announced today that it is scheduled to join the US broad market Russell 3000, Russell Global, and Russell Microcap Indexes when Russell Investments reconstitutes its comprehensive set of US and global equity indexes on June 25, 2012. This is according to a list of additions posted on June 8 on the Russell website at www.russell.com/indexes. The Russell 3000 index serves as the US component for the Russell Global index.
The Russell Indexes are widely used by investment managers and institutional investors for index funds and as industry-wide benchmarks for both passive and active investment strategies. According to Russell Investments, an industry-leading $3.9 trillion in assets are currently benchmarked to the various Russell indexes.
ImmunoCellular considers the imminent move of its stock into the Russell indexes to be an important step in the company’s efforts to increase liquidity in its stock and broaden its investor base among major institutional investors. It believes the timing of its inclusion into the indexes is ideal as it should increase investor awareness ahead of the clinical results from its Phase II trial of ICT-107.
To learn more about ImmunoCellular Therapeutics and its ICT-107 product candidate, please visit the company’s website at www.imuc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
